Efficacy and Safety of Darolutamide in Black/African–American Patients from the Phase III ARAMIS Study

References

• Siegel RL , MillerKD, FuchsHE, JemalA. Cancer statistics, 2021.CA Cancer J. Clin.71(1), 7–33 (2021).
   PubMed Web of Science ®Google Scholar
• Bray F , FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Taitt HE . Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location.Am. J. Mens Health12(6), 1807–1823 (2018).
   PubMed Web of Science ®Google Scholar
• Siegel RL , MillerKD, FuchsHE, JemalA. Cancer statistics, 2022.CA Cancer J. Clin.72(1), 7–33 (2022).
   PubMed Web of Science ®Google Scholar
• Thompson I , TangenC, TolcherA, CrawfordE, EisenbergerM, MoinpourC. Association of African–American ethnic background with survival in men with metastatic prostate cancer.J. Natl Cancer Inst.93(3), 219–225 (2001).
   PubMed Web of Science ®Google Scholar
• Halabi S , DuttaS, TangenCMet al. Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel. J. Clin. Oncol. 37(5), 403–410 (2019).
   PubMed Web of Science ®Google Scholar
• Lewis DD , CroppCD. The impact of African ancestry on prostate cancer disparities in the era of precision medicine.Genes (Basel)11(12), 1471 (2020).
   PubMed Web of Science ®Google Scholar
• Steele CB , LiJ, HuangB, WeirHK. Prostate cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study.Cancer123(Suppl. 24), 5160–5177 (2017).
   PubMedGoogle Scholar
• Yamoah K , LeeKM, AlbaPRet al. Defining racial disparities across the prostate cancer disease continuum in an equal access-to-care setting within the nation's largest healthcare network. Int. J. Radiat. Oncol. 111(3), S135–S136 (2021).
   PubMed Web of Science ®Google Scholar
• Rayford W , BeksacAT, AlgerJet al. Comparative analysis of 1152 African–American and European–American men with prostate cancer identifies distinct genomic and immunological differences. Commun. Biol. 4(1), 670 (2021).
   PubMed Web of Science ®Google Scholar
• Khashab T , LeAD, CohenSet al. Genomic landscape of advanced prostate cancer in racial minority populations: real-world experience in a safety-net hospital oncology clinic [abstract]. J. Clin. Oncol. 39(Suppl. 6), 14 (2021).
   Web of Science ®Google Scholar
• Powell IJ , DysonG, LandSet al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol. Biomarkers Prev. 22(5), 891–897 (2013).
   PubMed Web of Science ®Google Scholar
• Yamoah K , JohnsonMH, ChoeurngVet al. Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer. J. Clin. Oncol. 33(25), 2789–2796 (2015).
   PubMed Web of Science ®Google Scholar
• Singh SK , LillardJWJr, SinghR. Molecular basis for prostate cancer racial disparities.Front Biosci. (Landmark Ed.)22, 428–450 (2017).
   PubMed Web of Science ®Google Scholar
• Echevarria MI , AwasthiS, ChengCHet al. African American specific gene panel predictive of poor prostate cancer outcome. J. Urol. 202(2), 247–255 (2019).
   PubMed Web of Science ®Google Scholar
• Gaston KE , KimD, SinghS, FordOH3rd, MohlerJL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer.J. Urol.170(3), 990–993 (2003).
   PubMed Web of Science ®Google Scholar
• Moses KA , OromH, BraselA, GaddyJ, UnderwoodW3rd. Racial/ethnic disparity in treatment for prostate cancer: does cancer severity matter?Urology99, 76–83 (2017).
   PubMed Web of Science ®Google Scholar
• Dess RT , HartmanHE, MahalBAet al. Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 5(7), 975–983 (2019).
   PubMed Web of Science ®Google Scholar
• George DJ , HalabiS, HeathEIet al. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer 127(16), 2954–2965 (2021).
   PubMed Web of Science ®Google Scholar
• Moilanen AM , RiikonenR, OksalaRet al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci. Rep. 5, 12007 (2015).
   PubMed Web of Science ®Google Scholar
• Zurth C , SandmanS, TrummelD, SeidelD, NubbemeyerR, GieschenH. Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography [abstract].J. Clin. Oncol.37(Suppl. 7), 156 (2019).
   Web of Science ®Google Scholar
• Shore N , ZurthC, FrickeRet al. Evaluation of clinically relevant drug–drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 14(5), 527–539 (2019).
   PubMed Web of Science ®Google Scholar
• Fizazi K , ShoreN, TammelaTLet al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 380(13), 1235–1246 (2019).
   PubMed Web of Science ®Google Scholar
• Fizazi K , ShoreN, TammelaTLet al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N. Engl. J. Med. 383(11), 1040–1049 (2020).
   PubMed Web of Science ®Google Scholar
• Riviere P , LutersteinE, KumarAet al. Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer 126(8), 1683–1690 (2020).
   PubMed Web of Science ®Google Scholar
• Meunier ME , BlanchetP, NeuzilletY, LebretT, BrureauL. A review of new hormonal therapies for prostate cancer in black men: is there enough data?BMC Cancer21(1), 61 (2021).
   PubMed Web of Science ®Google Scholar
• Vengaloor Thomas T , GordyXZ, LiretteSTet al. Lack of racial survival differences in metastatic prostate cancer in National Cancer Data Base (NCDB): a different finding compared to non-metastatic disease. Front Oncol. 10, 533070 (2020).
   PubMed Web of Science ®Google Scholar